Record growth, profit flat—the leverage problem

EPL delivered a masterclass in revenue momentum—all regions grew, all product categories contributed, pricing held. But profit didn't follow. This is not a simple miss; it's a structural sign: the company is investing ahead of the curve, absorbing working capital, and facing a tax headwind—none of which will reverse quickly.

Follow the money: revenue up 25.3%, but EBITDA growth only 15.2% and PAT down 0.8%. The leverage chain broke. Capex absorption: Management is running capex 'ahead of the curve'—new production lines in Europe (Poland centralization, extruded capacity), B&C centers of excellence, regional salesforces (U.S., Brazil split by category). Depreciation on this capex is hitting the P&L now; revenue payoff is years out. This is strategic but compresses near-term returns. Working capital build: Net debt rose ~₹180 Cr in the quarter, largely inventory (pricing cycle + safety stock for supply security). If not unwound, this is a cash-generation headwind. Tax rate jump: ETR spiked to ~20% this quarter vs. 14–18% historically. Management guided 20–22% full-year (multi-country blended), but Q1's 20%+ reflects lapping a very low prior-year base. This timing drag is real for Q1 comparisons. The EBITDA miss: Delivered 18.8% vs. 20% target. Management claims 19.6% 'underlying' excluding pass-through pricing, but even that misses guidance by 40 bps. EBITDA growth (15.2%) lagged revenue (25.3%), signaling margin compression below the 20% line despite pricing power.

Revenue guidance raised: From early double digits (11–13%) to 'high teens' for the next few quarters. Drivers: B&C momentum (targeting market share 8%→16%), Oral Care recovery (24% this Q, driven by service reliability during crisis), and Thailand operations now live (EAP grew 34%, highest region). This is credible—growth is broad-based and all segments contributed. Margin guidance reaffirmed (with caveats): EBITDA 20% maintained, but Q1 delivered 18.8%. Management attributes 120 bps miss to pass-through pricing and timing of investments. Underlying rate claimed at 19.6%, but the gap remains. Capex elevated and strategic: No specific ₹ amount disclosed, but management confirmed 'ahead of curve' capex: B&C centers of excellence, regional salesforces (U.S. Oral vs. B&C split), Poland printing centralization, extruded production. Multi-year bets; near-term ROCE and free cash flow under pressure. Indovida acquisition progressing: CCI approval received; transaction 'on track to complete within planned timeline.' Indovida's Q1: ₹383 Cr EBITDA, 62% growth, 27% margin—strong validation. But deal not closed; merger contingency remains. Europe execution under spotlight: 20.2% revenue growth, but margins pressured by 'operational challenges.' Management gave 'disproportionate focus' assurance but no specifics on issues, magnitude, or recovery timeline.

The initial market reaction was bullish: day-1 pop +3.33%, holding at +4.33% by day-5. The pop held, suggesting the market accepted the revenue beat and raised guidance as sufficient cover for the profit miss. But the investor base is shifting. Foreign institutions trimmed 3.15 percentage points (FII 17.23%→14.08%), while domestic institutions accumulated 3.6 points (DII 10.20%→13.80%). This tells a story: international money taking profits; local capital stepping in on the dip. The divergence suggests overseas investors are cautious on the leverage story, while domestic buyers see value in the long-term thesis (B&C, Indovida, Thailand). The stock is trading ₹251.94, up 42.82% from its 52-week low but 8.04% below its all-time high of ₹273.96. It is above its 20-, 50-, and 200-day moving averages—technically sound—but RSI 66.6 is neutral, not overbought. The tape supports the fundamental verdict: genuine growth, real caution on profit.

Q2 PAT growth rate. If it's positive and in double digits, the capex and working capital headwinds were Q1-specific and management guidance is sound. If it's flat or negative again, the leverage problem is structural and the full-year 'double-digit PAT growth' claim is in jeopardy. That one number—Q2 profit—resolves the quarter's real debate.